Potential Neuroprotective Agents for Facial Nerve Injury

AB35. Future potential of the neuroprotective agent (local application) for the nerve injury in radical prostatectomy

Botulinum toxin has recently been approved by the United States FDA for idiopathic and neurogenic detrusor overactivity (overactive bladder). This is an easy clinic procedure that can be performed cystoscopically under local anesthesia with very good success. We will discuss the mechanism of action of this drug, the efficacy, and clinical precautions to ensure a safe and successful result for t...

Neuroprotective agents in severe head injury.

Neuroprotective agents for neonatal hypoxic-ischemic brain injury.

Hypoxic-ischemic (H-I) brain injury in newborns is a major cause of morbidity and mortality that claims thousands of lives each year. In this review, we summarize the promising neuroprotective agents tested on animal models and pilot clinical studies of neonatal H-I brain injury according to the different phases of the disease. These agents target various phases of injury including the early ph...

Facial nerve injury. A short review.

Despite considerable advances in technique, experience and skill, the precise place of surgery in the treatment of facial nerve injury remains uncertain. The mechanism of delayed facial palsy is not yet clear, and there is still debate about the value of tests for early evidence of denervation. Recent literature has been reviewed.

The surgical management of facial nerve injury.

Treatment of facial nerve injuries depends upon a detailed understanding of its anatomic course, accurate clinical examination, and timely and appropriate diagnostic studies. Reconstruction depends upon the extent of injury, the availability of the proximal stump. and the time since injury and duration of muscle denervation. Although no alternative is perfect, these techniques, in combination w...